Clinical trial · Interventional
MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases
Diagnostic Accuracy of Delayed MRI Contrast Enhancement Characteristics and Radiation Necrosis Following Stereotactic Radiosurgery (SRS) for Brain Metastases
NCT04246879CI-TRIAL-00110675active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test whether an additional magnetic resonance image (MRI) sequence can improve the ability to distinguish radiation damage from tumor recurrence in participants with brain metastasis who have previously been treated with stereotactic radiosurgery (SRS).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MRI
- interventionNames
- Other: MRI
Primary outcomes (2)
- measure
- number of positive MRI sequences along with positive tumor biopsies
- timeFrame
- baseline
- description
- true tumor will be detected by delayed MRI as determined by biopsy
- measure
- number of negative MRI sequences along with negative tumor biopsies
- timeFrame
- baseline
- description
- absence of tumor will be detected by delayed MRI as determined by biopsy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients, age ≥18 * Metastatic malignancy with at least 1 brain metastasis previously treated with SRS * Patients may have also received whole brain radiation therapy (WBRT) for management of brain metastatic disease but this is not required for study participation * Patients must have been diagnosed with a metastatic solid tumor of any histological type except small cell lung cancer (SCLC), or lymphoma. * Radiographic progression on post-SRS imaging at previously treated SRS site(s) * Must be a candidate for brain surgery as determined by treating neurosurgeon and/or anesthesia team * Patients must sign study-specific informed consent prior to study entry Exclusion Criteria: * Poor surgical candidate as determined by treating neurosurgeon and/or anesthesia team * Unable to undergo contrasted MRI (e.g. incompatible medical device, inadequate renal function per standard institutional clinical protocol, contrast allergy) * Small cell lung cancer (SCLC) or lymphoma histology
References
Publications (0)
Data not yet available
No reference posted for this study.